Rivastigmine Transdermal System Patch, Extended Release
Product Images NDC 72162-1609

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Rivastigmine Transdermal System (NDC 72162-1609). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721621609)

Each patch of 10 cm2 contains 18 mg of Rivastigmine base with an in vivo release rate of 9.5 mg/24 hours. It is recommended to store the Transdermal System at 25°C (77°F) with excursions allowed between 15°C-30°C (59°F-86°F). This product is for transdermal use only and should be applied immediately after removal from the pouch. Be cautious not to use any patch that is damaged or shows signs of tampering. The package insert contains a QR code for dosage, administration, and discarding instructions.*

FDA Label Image

Chemical Structure (Rivastigmine 01)

FDA Label Image

Figure 1 (Rivastigmine 02)

FDA Label Image

Figure 2 (Rivastigmine 03)

Rivastigmine levels at various dosages of 13.3 mg/24 hours, 9.5 mg/24 hours, and 4.6 mg/24 hours with the corresponding number of participants in each group (n=19, n=22, n=22) were measured. The levels were found to be 20 ng/mL, 16 ng/mL, and 12 ng/mL respectively.*

FDA Label Image

Figure 3 (Rivastigmine 04)

This appears to be a report showing the least square means with standard error of the mean (SEM) for changes in ADAS-Cog ratings from baseline at 16 weeks during treatment. The data includes different dosages of medication and placebo, with labels indicating clinical improvement or decline.*

FDA Label Image

Figure 4 (Rivastigmine 05)

FDA Label Image

Figure 5 (Rivastigmine 06)

This text provides information about changes in ADCS-IADL scores from baseline, indicating clinical improvement and decline over time in a study comparing two different doses of Fivastomine Transdermal System (3.3 mg/24hr and 9.5 mg/24hr). The data is presented in a table showing the weeks of treatment.*

FDA Label Image

Figure 6 (Rivastigmine 07)

This text provides information about clinical improvement over weeks of treatment using ADAS-Cog change from baseline data. It appears to be a chart or graph displaying data points at various time intervals.*

FDA Label Image

Figure 7 (Rivastigmine 08)

FDA Label Image

Figure 8 (Rivastigmine 09)

FDA Label Image

Figure A (Rivastigmine 10)

Protective liners for Rivastigmine Transdermal System pouch. These liners help protect the medication pouch and provide added security during storage and use. Ideal for keeping the medication patch safe and secure.*

FDA Label Image

Figure B (Rivastigmine 11)

This text appears to be a list of body parts where a specific action or treatment might occur. It mentions parts like the upper arm, side of the chest, upper back, and lower back on either the left or right side. This could be referencing locations for procedures, assessments, or exercises related to these areas of the body.*

FDA Label Image

Figure C (Rivastigmine 12)

FDA Label Image

Figure D (Rivastigmine 13)

FDA Label Image

Figure E (Rivastigmine 14)

FDA Label Image

Figure F (Rivastigmine 15)

FDA Label Image

Figure G (Rivastigmine 16)

FDA Label Image

Figure H (Rivastigmine 17)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.